GERN · Company research

Geron Corporation

1 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

Trial resultsGERNGeronH2 2026

Geron expects to report results from its Phase 3 study of imetelstat (RYTELO) for JAK-inhibitor relapsed/refractory intermediate-2/high-risk myelofibrosis in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details

Entry

IMpactMF Phase 3 interim analysis (overall survival) in relapsed/refractory myelofibrosis · Clinical trial results (readout / topline data)

Drug

imetelstat (RYTELO)

For

JAK-inhibitor relapsed/refractory intermediate-2/high-risk myelofibrosis

Stage

Phase 3 · the last stage before a drug can be approved

When

H2 2026 · the company gave a window, not a day

Source note

Prior guidance placed the interim OS analysis in 2H 2026; on the Q2 2026 call management said projected timelines are unchanged but it is evaluating a modification to the interim event threshold, calls a positive interim an upside scenario, and keeps final OS analysis in 2H 2028 as base case. Timing risk is real.

Checked

Checked by a person when it was added

Verify it

Source: fool.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
GERN headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

ConferenceGERNGeronMay 12, 2026

Geron presented data on RYTELO (imetelstat) for lower-risk myelodysplastic syndromes at a medical meeting on May 12, 2026. The linked source has the details.

More details

Entry

First real-world RYTELO study in LR-MDS to be presented at EHA 2026 · Data presented at a medical meeting

Drug

RYTELO (imetelstat)

For

lower-risk myelodysplastic syndromes

Stage

real-world evidence (post-approval)

When

May 12, 2026

Source note

Geron announced that the first real-world evidence study of imetelstat in lower-risk MDS — an investigator-sponsored Moffitt Cancer Center analysis in heavily transfusion-dependent, post-luspatercept patients — would be presented at the EHA 2026 Congress; results were generally consistent with the Phase 3 IMerge trial.

Checked

Checked by a person when it was added

Verify it

Source: stocktitan.net ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
GERN headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ApprovalGERNGeronJun 6, 2024

The FDA approved Geron’s Rytelo (imetelstat) for Lower-risk MDS anemia on Jun 6, 2024. The company can now sell it in that market.

More details

Entry

FDA approval of Rytelo · Regulatory approval

Drug

Rytelo (imetelstat)

For

Lower-risk MDS anemia

When

Jun 6, 2024

Checked

Checked by a person when it was added

Verify it

SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
Drugs@FDA ↗ — search the drug name for approval letters
GERN headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to GERN.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.